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The metabolic consequences of the NADP+- dependent
isocitrate dehydrogenase (IDH) 1 mutation was studied
quantitatively in glioblastoma, the most aggressive form of
brain tumor. The mutation is found in 70-80% of second-
ary glioblastoma. Metabolic rewiring of cells due to the
mutation causes gliomagenesis by the production of
2-hydroxyglutarate. On the other hand, glioblastoma
patients with the IDH1 mutation have a significant
survival benefit of approx. one year. We found that the
NADPH production capacity in glioblastoma is reduced
by 38% when IDH1 is mutated [1]. We hypothesized that
this reduced production capacity of NADPH, a major
metabolite involved in detoxification processes, renders
glioblastoma cells less resistant against irradiation and
chemotherapy and thus prolong patient survival [2]. We
also demonstrated that cellular metabolism is rewired in
IDH1-mutated glioblastoma cells by elevated mitochon-
drial activity [3]. Further metabolic studies of human and
rodent tissues showed that IDH activity is responsible for
65% of the NADPH production capacity in human brain
and only for 15% in rodent brain whereas the pentose
phosphate pathway was responsible for 85% of the
NADPH production capacity in rodent tissues [4].
It explains why the pentose phosphate pathway was always
linked with cancer and not IDH because most studies on
metabolism and cancer have been performed in rodents.
In conclusion, our metabolic study strongly suggests
that the reduced NADPH production capacity in
IDH1-mutated gliomablastoma makes cancer cells less
resistant and as a consequence is at least partly responsible
for prolonged patient survival.
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